Evidence map›Paper›PMID 37442829›Full record

ArticlePsychopharmacology2023

Atypical antipsychotics attenuate MK801-induced social withdrawal and hyperlocomotion in the RHA rat model of schizophrenia-relevant features.

Daniel Sampedro-Viana, Toni Cañete, Francesco Sanna, Ignasi Oliveras, Valeria Lavín, Pilar Torrecilla, Cristóbal Río-Álamos, Carles Tapias-Espinosa, Ana Sánchez-González, Adolf Tobeña and 1 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Daniel Sampedro-VianaDepartment of Psychiatry & Forensic Medicine, Institute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain.ORCID http://orcid.org/0000-0003-3922-4039
Toni CañeteDepartment of Psychiatry & Forensic Medicine, Institute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain.
Francesco SannaDepartment of Life & Environmental Sciences, University of Cagliari, 09042, Monserrato, CA, Italy.
Ignasi OliverasDepartment of Psychiatry & Forensic Medicine, Institute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain.
Valeria LavínDepartment of Clinical & Health Psychology, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain.
Pilar TorrecillaDepartment of Clinical & Health Psychology, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain.
Cristóbal Río-ÁlamosDepartment of Psychology, School of Medicine, Austral University of Chile, Valdivia, Chile.
Carles Tapias-EspinosaDepartment of Psychiatry & Forensic Medicine, Institute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain.
Ana Sánchez-GonzálezDepartment of Psychiatry & Forensic Medicine, Institute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain.
Adolf TobeñaDepartment of Psychiatry & Forensic Medicine, Institute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain.
Alberto Fernández-TeruelDepartment of Psychiatry & Forensic Medicine, Institute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, 08193, Barcelona, Spain. Albert.Fernandez.Teruel@uab.cat.
Universitat Autònoma de Barcelona · ESAustral University of Chile · CLUniversity of Cagliari · IT

Funding

Agencia Nacional de Investigación y Desarrollo 11190240Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya 2017SGR-1586Ministerio de Ciencia e Innovación PID2020-114697GB-I00Ministerio de Ciencia e Innovación PSI2017-82257-P
6 · The paper itself

Abstract

rationaleThe administration of NMDA receptor (NMDAR) antagonists constitutes a widely used model that produce both positive (e.g., hyperactivity) and negative (e.g., social withdrawal) symptoms relevant for schizophrenia in rodents. These effects can be reversed with the administration of atypical (second and third generation) antipsychotics.

objectivesIn this study we combined the NMDAR-antagonist model with the Roman High-Avoidance (RHA) strain, a psychogenetically selected model of schizophrenia-relevant features. We also studied whether some atypical antipsychotic drugs (clozapine, ziprasidone, and aripiprazole) would be able to attenuate or reverse the behavioural alterations induced by MK801 and whether such effects might be dependent on the rat strain.

methodsMK801 dose-response study was conducted in RHA and Roman Low-Avoidance (RLA) male rats. After that, the 0.15 mg/kg MK801 dose was selected to carry out pharmacological studies versus atypical antipsychotics.

resultsIn the first experiment we establish that MK801 (dizocilpine), a NMDAR antagonist, produces dose-related hyperactivity and social withdrawal, which are more marked in RHA than RLA rats. The administration of the atypical antipsychotics clozapine (2.5 mg/kg) or ziprasidone (2.5 mg/kg) partially reversed or attenuated some of the social behaviour deficits and hyperactivity induced by the administration of MK801. Aripiprazole (3 mg/kg), a third-generation antipsychotic, reversed or attenuated the social preference deficit, the hyperactivity and the impairment of social latency induced by MK801.

conclusionsThese results seem to be in line with previous studies with the NMDAR-antagonist model and add face (MK801-induced social withdrawal and hyperactivity) and predictive (attenuation of MK801-induced effects by atypical antipsychotics) validity to the RHA rat strain as a model of schizophrenia-relevant features.

Indexed as

Antipsychotic AgentsClozapineSchizophreniaAnimalsAripiprazoleDizocilpine MaleateMalePiperazinesRatsSocial IsolationThiazolesAntipsychotic AgentsAripiprazoleClozapineDizocilpine MaleatePiperazinesThiazolesziprasidoneAtypical antipsychoticsNegative symptomsNMDAR antagonistRHA and RLA ratsSchizophreniaSocial withdrawal

Identifiers

PMID37442829
OpenAlexW4384198518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.